EFS results based on asparaginase, dexrazoxane, and CNS randomization. (A) EFS results of asparaginase randomization. The 5-year EFS for patients randomized to Erwinia asparaginase was 78% ± 4% compared with 89% ± 3% for those randomized to E coli asparaginase (P = .01). (B) EFS results of dexrazoxane randomization (HR patients only). The 5-year EFS for patients randomized to doxorubicin with dexrazoxane was 76% ± 4% compared with 77% ± 4% for those randomized to doxorubicin alone (P = .99). (C) EFS results of CNS randomization (SR patients only). The 5-year EFS for patients randomized to intrathecal therapy only (no radiation) was 83% ± 4% compared with 86% ± 4% for those randomized to 18-Gy cranial radiation (P = .26).